HIV-1 Immune evasion: The main obstacle toward a successful vaccine
Authors:
- Mona Sadat LarijaniMLMona Sadat Larijani
- Seyed Mehdi SadatSSSeyed Mehdi Sadat
- Amitis RamezaniARAmitis Ramezani
Open Access
- 19 December 2018
- journal article
- Published by Heighten Science Publications Corporation in Archives of Asthma, Allergy and Immunology
- Vol. 2 (1) , 013-015
Abstract
It is estimated that there are 36.9 million individuals living with HIV-1 from who 21.7 million patients receiving antiretroviral therapy (ART) [1,2].Keywords
This publication has 19 references indexed in Scilit:
- Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1ISRN Aids, 2013
- High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South AfricaScience, 2013
- A 2020 vision for vaccines against HIV, tuberculosis and malariaNature, 2011
- The immune response during acute HIV-1 infection: clues for vaccine developmentNature Reviews Immunology, 2009
- Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell TransplantationNew England Journal of Medicine, 2009
- The Challenge of HIV-1 Subtype DiversityNew England Journal of Medicine, 2008
- HIV-1 Accessory Proteins—Ensuring Viral Survival in a Hostile EnvironmentCell Host & Microbe, 2008
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences, 2008
- Regulating The Functions of The HIV-1 Matrix ProteinAIDS Research and Human Retroviruses, 2007
- HIV-1: Fifteen Proteins and an RNAAnnual Review of Biochemistry, 1998